Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene to Generate New mAbs Using Harbour BioMed's Mouse Platform

publication date: Jan 8, 2018

Beijing's BeiGene licensed multi-year rights to use Harbour BioMed's H2L2 transgenic mouse platform, which generates fully human therapeutic monoclonal antibodies. Harbour BioMed, a Shanghai company, also entered another agreement, this one with ImmunoChina Pharma of Beijing, to develop fully human monoclonal antibody fragments for use in Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy. ImmunoChina is developing CAR-T therapies for hematological and solid tumor cancers. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.